MediWound Ltd. (NASDAQ:MDWD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of MediWound Ltd. (NASDAQ:MDWD) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $33.50.

A number of equities analysts have issued reports on MDWD shares. Wall Street Zen upgraded MediWound from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd.

MediWound Trading Down 3.4%

Shares of MDWD stock opened at $17.12 on Thursday. The firm has a fifty day simple moving average of $18.03 and a two-hundred day simple moving average of $17.94. MediWound has a 12 month low of $14.14 and a 12 month high of $22.50. The firm has a market capitalization of $219.82 million, a PE ratio of -9.01 and a beta of 0.13.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. The firm had revenue of $5.43 million during the quarter, compared to analysts’ expectations of $6.56 million. On average, equities analysts predict that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of institutional investors have recently added to or reduced their stakes in MDWD. Quarry LP purchased a new stake in MediWound in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets increased its position in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in MediWound in the 4th quarter valued at $109,000. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.